1-carbamimidamido-N-(2-phenylethyl)methanimidamide

• ChemBase编号: 790
• 分子式: C10H15N5
• 平均质量: 205.2596
• 单一同位素质量: 205.13274551
• SMILES: c1(CCNC(=N)NC(=N)N)ccccc1
• Canonical SMILES: N=C(NC(=N)N)NCCc1ccccc1
• InChI: InChI=1S/C10H15N5/c11-9(12)15-10(13)14-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H6,11,12,13,14,15)
• InChIKey: ICFJFFQQTFMIBG-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 1-carbamimidamido-N-(2-phenylethyl)methanimidamide
• IUPAC传统名: phenethylbiguanide
• 商标名: Azucaps; Cronoformin; D Bretard; DBI; DB Comb; DB-Retard; DBI Monohydrochloride; Debeone; Debinyl; Diabis; Dibein; Dibiraf; Dibotin; Dipar; Feguanide; Fenfoduron; Fenormin; Glukopostin; Glyphen; Insoral; Lentobetic; Meltrol; Meltrol-50; Normoglucina; Phenformix; Retardo
• 别名: Fenformina [INN-Spanish]; Fenformin; N-Phenethylbiguanide Hydrochloride; Phenethylbiguanide Hydrochloride; PEDG; Phenethyldiguanide; Phenformin HCl; Phenformin Hydrochloride; Phenformine; Phenformine HCl; Phenformine [INN-French]; Phenforminum [INN-Latin]; Phenoformine Hydrochloride; Phenylethylbiguanide; Beta-Phenethylbiguanide; Beta-Phenethybiguanide; Beta-Pebg; Phenformin

登记号

• CAS号: 114-86-3
• PubChem SID: 160964253; 46505230
• PubChem CID: 8249

理论计算性质

JChem

• 质子受体: 5
• 质子供体: 5
• LogD (pH = 5.5): -3.9934607
• LogD (pH = 7.4): -3.7257519
• Log P: 0.832729
• 摩尔折射率: 80.7156 cm^3
• 极化性: 22.477764 Å^3
• 极化表面积: 97.78 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: -0.72
• LOG S: -2.95
• 溶解度: 2.32e-01 g/l

分子性质

理化性质

• 溶解度: 210 mg/mL
• 疏水性(logP): 0.1

详细说明

DrugBank - DB00914

• Drug Groups: approved; withdrawn
• Description: A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
• Indication: For the reatment of type II diabetes mellitus.
• Pharmacology: Used to treat diabetes, phenformin is a biguanide (contains 2 guanidino groups) hypoglycemic agent with actions and uses similar to those of metformin (Glucophage). Both drugs work by (1) decreasing the absorption of glucose by the intestines, (2) decreasing the production of glucose in the liver, and by (3) increasing the body's ability to use insulin more effectively. More specifically, phenformin improves glycemic control by improving insulin sensitivity. Phenformin is generally considered to be associated with an unacceptably high incidence of actic acidosis. In general biguanides should be used only in stable type II diabetics who are free of liver, kidney and cardiovascular problems and who cannot be controlled with diet.
• Affected Organisms: Humans and other mammals
• References: Enia G, Garozzo M, Zoccali C: Lactic acidosis induced by phenformin is still a public health problem in Italy. BMJ. 1997 Nov 29;315(7120):1466-7. [Pubmed] ; Rosand J, Friedberg JW, Yang JM: Fatal phenformin-associated lactic acidosis. Ann Intern Med. 1997 Jul 15;127(2):170. [Pubmed]
• External Links: Wikipedia

参考文献

• Enia G, Garozzo M, Zoccali C: Lactic acidosis induced by phenformin is still a public health problem in Italy. BMJ. 1997 Nov 29;315(7120):1466-7. Pubmed
• Rosand J, Friedberg JW, Yang JM: Fatal phenformin-associated lactic acidosis. Ann Intern Med. 1997 Jul 15;127(2):170. Pubmed